Premium
Chemical Probes for Drug‐Resistance Assessment by Binding Competition (RABC): Oseltamivir Susceptibility Evaluation
Author(s) -
Cheng TingJen R.,
Wang ShiYun,
Wen WenHsien,
Su ChingYao,
Lin Mengi,
Huang WenI,
Liu MingTsan,
Wu HoSheng,
Wang NungSen,
Cheng ChungKai,
Chen ChunLin,
Ren ChienTai,
Wu ChungYi,
Fang JimMin,
Cheng YihShyun E.,
Wong ChiHuey
Publication year - 2013
Publication title -
angewandte chemie international edition
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 5.831
H-Index - 550
eISSN - 1521-3773
pISSN - 1433-7851
DOI - 10.1002/anie.201204062
Subject(s) - zanamivir , oseltamivir , neuraminidase , neuraminidase inhibitor , drug resistance , virology , drug , chemistry , biology , microbiology and biotechnology , medicine , virus , pharmacology , covid-19 , infectious disease (medical specialty) , disease , pathology
The wizard of OS (resistance) : The binding difference of neuraminidase inhibitors (zanamivir versus oseltamivir (OS)) was used to establish an assay to identify the influenza subtypes that are resistant to OS but still sensitive to zanamivir (see scheme). This assay used a zanamivir‐biotin conjugate to determine the OS susceptibility of a wide range of influenza viruses and over 200 clinical isolates.